Evommune (EVMN) Common Equity (2024 - 2026)

Evommune (EVMN) has 3 years of Common Equity data on file, last reported at $304.6 million in Q1 2026.

• On a quarterly basis, Common Equity rose 292.47% year-over-year to $304.6 million in Q1 2026; TTM through Mar 2026 was $304.6 million, a 292.47% increase from a year earlier, with the FY2025 full-year figure at $205.6 million, up 242.52% from the prior year.
• Common Equity for Q1 2026 stood at $304.6 million, up from $205.6 million in the prior quarter.
• Over the last five years, Common Equity for EVMN reached as high as $304.6 million in Q1 2026 and fell as low as -$183.1 million in Q3 2025.
• Historically, Common Equity has averaged -$16.3 million across 3 years, with a median of -$133.4 million in 2024.
• Across the five-year window, Common Equity slumped 49.47% in 2025 and surged 292.47% in 2026, its largest moves.
• Year by year, Common Equity stood at -$144.2 million in 2024, then jumped by 242.52% to $205.6 million in 2025, then surged by 48.15% to $304.6 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $304.6 million in Q1 2026, $205.6 million in Q4 2025, and -$183.1 million in Q3 2025.